MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Supernus Pharmaceuticals Inc

Fechado

SetorSaúde

47.93 -0.23

Visão Geral

Variação de preço das ações

24h

Atual

Mín

47.27

Máximo

48.43

Indicadores-chave

By Trading Economics

Rendimento

34M

22M

Vendas

16M

165M

P/E

Médio do Setor

41.391

35.739

Margem de lucro

13.598

Funcionários

674

EBITDA

20M

38M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

-0.6% downside

Dividendos

By Dow Jones

Próximos Ganhos

3 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

594M

2.7B

Abertura anterior

48.16

Fecho anterior

47.93

Sentimento de Notícias

By Acuity

50%

50%

149 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Supernus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de out. de 2025, 23:30 UTC

Ações em Alta

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 de out. de 2025, 21:21 UTC

Ganhos

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 de out. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 de out. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 de out. de 2025, 23:39 UTC

Conversa de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 de out. de 2025, 23:00 UTC

Conversa de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Scales's JV Buyout Lauded by Bull -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Forex and Fixed Income Roundup: Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de out. de 2025, 21:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 de out. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

2 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

2 de out. de 2025, 20:49 UTC

Aquisições, Fusões, Aquisições de Empresas

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 de out. de 2025, 20:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 de out. de 2025, 19:20 UTC

Conversa de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 de out. de 2025, 19:10 UTC

Conversa de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 de out. de 2025, 19:04 UTC

Conversa de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 de out. de 2025, 18:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparação entre Pares

Variação de preço

Supernus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

-0.6% parte inferior

Previsão para 12 meses

Média 47.75 USD  -0.6%

Máximo 63 USD

Mínimo 40 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Supernus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

2

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.35 / 32.36Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

149 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
help-icon Live chat